|
May 28
|
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
|
|
May 25
|
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
|
|
May 21
|
Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't?
|
|
May 14
|
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
|
|
May 2
|
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
|
|
May 2
|
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
|
|
May 1
|
Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say
|
|
May 1
|
Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
|
|
May 1
|
Alkermes plc Reports First Quarter 2024 Financial Results
|
|
Apr 30
|
How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits?
|
|
Apr 24
|
Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Apr 24
|
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
|
|
Apr 22
|
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
|
|
Apr 17
|
Alkermes to Report First Quarter Financial Results on May 1, 2024
|
|
Apr 17
|
Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release
|
|
Apr 16
|
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
|
|
Apr 11
|
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
|
|
Apr 11
|
Alkermes' Innovations Are Transforming Mental Health Treatments
|
|
Apr 10
|
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
|
|
Apr 9
|
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
|